Gretai:6576

Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg

TAIPEI, , March 29, 2019 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today that it has submitted to the U.S. Food and Drug Administration a 505(b)(2) New Drug Application for LMIS 50 mg, a ready-to-use 6-month depot formulation of leuprolide mesylate. The a...

2019-03-30 04:06 788

Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer

TAIPEI, , February 21, 2019 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the topline results of FP-001 LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg phase 3 clinical trial, an open-label, single-arm study in subjects with Prostate Carcinoma. L...

2019-02-21 18:30 643

Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare

TAIPEI, , Feb. 11, 2019 /PRNewswire/ -- An exclusive license agreement for the commercialisation of Foresee Pharmaceutical's (6576.TWO) novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous depot formulations has been granted to Accor...

2019-02-11 18:30 521

Foresee Pharmaceuticals Announces Sr. VP of Pharmaceutics and Manufacturing Appointment

TAIPEI, , Nov. 15, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the appointment of Dr.Thomas Weitao Sun as the Senior Vice President of Pharmaceutics and Manufacturing. Dr. Thomas Sun is a successful executive with over 20 years of experience in ...

2018-11-15 20:33 322

Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator

TAIPEI, , July 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today that it has successfully completed a Phase 1 multiple ascending dose (MAD) clinical study with FP-045, its novel, potent, oral small-molecule ALDH2 activator being developed for the t...

2018-07-26 19:30 591

Foresee Pharmaceuticals and Megapharm Announce License and Distribution Agreement

TAIPEI, and RAANANA, Israel, Jan. 3, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), aTaiwan and US-based biopharmaceutical company and Megapharm Ltd. ("Megapharm"), a leadingIsrael -based biopharmaceutical company, announced today that they have entered into an ex...

2018-01-03 20:02 328

Foresee Pharmaceuticals and TRPharm Announce License and Distribution Agreement

TAIPEI, and ISTANBUL, Sept. 27, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), aTaiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish biopharmaceutical company, announced today that they have entered into an exclusive license and distributi...

2017-09-27 19:56 2107

Foresee Pharmaceuticals Announces CEO Appointment

TAIPEI, , July 31, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the appointment of Dr.Lawrence Gan to the position of Chief Executive Officer (CEO), effective onAug. 1st, 2017. Dr. Lawrence Gan will lead Foresee's global strategy including po...

2017-07-31 18:53 1910